



Multiple Bone Involvement in Low-grade Myofibroblastic Sarcoma Demonstrated on ¹⁸F-FDG PET/CT

Düşük Dereceli Miyofibroblastik Sarkomda ¹⁸F-FDG PET/CT'de Gösterilen Çoklu Kemik Tutulumu

© Hui Li*, © Xiaoyan Hou*, © Na Guo, © Le Song, © Weifang Zhang

Peking University Third Hospital, Department of Nuclear Medicine, Beijing, China

*Contributed equally to this work as first authors.

Abstract

A 68-year-old woman with low back pain for 2 months was admitted. T2-weighted fat-saturated imaging revealed hyperintense lesions in multiple lumbar regions, suggesting the possibility of bone metastases. Multiple osteolytic and mixed osteolytic-osteoblastic lesions with significant ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) uptake, as well as multiple osteoblastic lesions with mild ¹⁸F-FDG uptake, were observed on subsequent ¹⁸F-FDG positron emission tomography/computed tomography without an identifiable primary lesion. This patient was pathologically diagnosed with low-grade myofibroblastic sarcoma (LGMS) after biopsy and surgery. Although multiple bone involvement in LGMS is extremely rare, this case suggests that it should be considered in the differential diagnosis of multiple bone metastases.

Keywords: Low-grade myofibroblastic sarcoma, bone destruction, ¹⁸F-FDG PET/CT

Öz

Altmış sekiz yaşında kadın hasta 2 aydır bel ağrısı şikayetiyle başvurdu. T2 ağırlıklı yağa doymuş görüntülemeye birden fazla lomber bölgede hiperintens lezyonlar saptandı ve bu da kemik metastazı olasılığını düşündürdü. ¹⁸F-florodeoksiglukoz (¹⁸F-FDG) pozitron emisyon tomografisi/bilgisayarlı tomografisinde tanımlanabilir bir primer olmaksızın, belirgin ¹⁸F-FDG alımına sahip çoklu osteolitik ve mikst osteolitik-osteoblastik lezyonların yanı sıra hafif ¹⁸F-FDG alımına sahip çoklu osteoblastik lezyonlar gözlemlendi. Bu hastaya biyopsi ve cerrahi sonrasında patolojik olarak düşük dereceli miyofibroblastik sarkom (LGMS) tanısı konuldu. LGMS'de çoklu kemik tutulumu son derece nadir olmakla birlikte, bu olgu LGMS'nin çoklu kemik metastazlarının ayrıncı tanısında dikkate alınması gerektiğini düşündürmektedir.

Anahtar kelimeler: Düşük dereceli miyofibroblastik sarkom, kemik yıkımı, ¹⁸F-FDG PET/CT

Addresses for Correspondence: Prof. Weifang Zhang, Le Song, MD, Peking University Third Hospital, Department of Nuclear Medicine, Beijing, China
Phone: +15611963920 **E-mail:** tsy1997@126.com ORCID ID: orcid.org/0000-0003-3879-1285

Prof. Le Song, MD, Peking University Third Hospital, Department of Nuclear Medicine, Beijing, China
Phone: +86-010-82264935, **E-mail:** songle@bjmu.edu.cn ORCID ID: orcid.org/0000-0002-7532-7150

Received: 26.09.2023 **Accepted:** 25.03.2024 **Epub:** 06.06.2024



Copyright© 2024 The Author. Published by Galenos Publishing House on behalf of the Turkish Society of Nuclear Medicine.
This is an open access article under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND) International License.




Figure 1. A 68-years-old woman with low back pain for 2 months was admitted. T2-weighted fat-saturated imaging revealed heterogeneous hyperintense lesions in multiple lumbar regions, indicating the likelihood of bone metastases. To identify the primary lesion and determine the tumor stage, the ^{18}F -fluorodeoxyglucose (^{18}F -FDG) positron emission tomography/computed tomography (PET/CT) was performed (A, MIP; B, sagittal T2-weighted fat-saturated magnetic resonance imaging; C, sagittal CT; D, sagittal PET/CT; E, J, K, axial PET/CT; F, I, L, axial CT; G, H, M, axial PET). Multiple osteolytic (solid arrow) and mixed osteolytic-osteoblastic (bend arrow) lesions with significant ^{18}F -FDG uptake, as well as multiple osteoblastic lesions (dotted arrow) with mild ^{18}F -FDG uptake, were observed in the thoracic vertebra (black arrow), lumbar vertebra (red arrow), sacrum (yellow arrow), right 12th rib, left ilium (green arrow), left pubis (blue arrow), and femur (arrowhead), without an identifiable primary lesion. In addition, intense activity was found in the oral cavity and left cheek area, with no abnormalities detected on the corresponding CT scans, indicating unspecific uptake. This patient underwent biopsy of the left iliac region and surgery of L3 and was pathologically diagnosed with low-grade myofibroblastic sarcoma (LGMS). LGMS is a rare mesenchymal tumor that was previously thought to mainly originate from the head and neck region, but a recent study suggested it may be more common in the extremities (1,2). The majority of LGMS occurs in the soft tissue and is infrequent in the bone (2,3). The distal femur is the most prevalent site for bone LGMS, followed by the ilium, and the vertebrae are rare (3,4,5). LGMS has been described as having a low-grade malignant potential that may locally recur and less frequently metastases (2). Multifocal involvement is extremely rare, with only one case of multicentric soft tissue involvement described by Wechalekar et al. (6). We report an extremely rare LGMS case of multiple bone involvement (multiple vertebrae, rib, ilium, pubis, and femur) without any soft tissue lesions. Furthermore, in this case, different types of bone destruction (osteolytic, mixed osteolytic-osteoblastic, and osteoblastic) were observed, which is quite different from the primary and metastatic bone lesions in the previous studies, which typically manifest as osteolytic bone destruction (1,4,5,7,8). ^{18}F -FDG PET/CT scan is an important approach in differentiating malignant sarcomatous lesions from benign lesions, especially for the equivocal lesions on conventional imaging, as well as a primary diagnostic tool for metastatic lesion detection (9,10). The presence of primary bone LGMS on the ^{18}F -FDG PET/CT scan has been reported by Hou et al. (8). To the best of our knowledge, this is the first case of LGMS involving numerous bones and causing different types of bone destruction with heterogeneous ^{18}F -FDG uptake on the ^{18}F -FDG PET/CT. Despite its rarity, this case suggests that LGMS with multiple bone involvement should be considered when multiple bone metastases are suspected.

Ethics

Informed Consent: The written informed consent has been obtained from the patient.

Authorship Contributions

Concept: L.S., W.Z., Design: L.S., W.Z., Data Collection or Processing: X.H., Analysis or Interpretation: X.H., Literature Search: H.L., N.G., Writing: H.L.

Conflict of Interest: No conflicts of interest were declared by the authors.

Financial Disclosure: This work was supported by the Key Clinical Projects of Peking University Third Hospital (no.: BYSY2022060).

References

1. San Miguel P, Fernández G, Ortiz-Rey JA, Larrauri P. Low-grade myofibroblastic sarcoma of the distal phalanx. *J Hand Surg Am.* 2004;29:1160-1163.
2. Chan JY, Gooi Z, Wong EW, Ng SK, Tong MC, Vlantis AC. Low-grade myofibroblastic sarcoma: A population-based study. *Laryngoscope.* 2017;127:116-121.
3. Hadjigeorgiou GF, Samaras V, Varsos V. Low-grade myofibroblastic sarcoma of the thoracic spine: report of an extreme rare case. *Br J Neurosurg.* 2017;31:731-733.
4. Watanabe K, Ogura G, Tajino T, Hoshi N, Suzuki T. Myofibrosarcoma of the bone: a clinicopathologic study. *Am J Surg Pathol.* 2001;25:1501-1507.
5. Saito T, Mitomi H, Kurisaki A, Torigoe T, Takagi T, Suehara Y, Okubo T, Kaneko K, Yao T. Low-grade myofibroblastic sarcoma of the distal femur. *Int J Surg Case Rep.* 2013;4:195-199.
6. Wechalekar MD, Ayres O, Farshid G, Clayer M, Cleland LG. Multicentric myofibroblastic sarcoma. *BMJ Case Rep.* 2014;2014:bcr2013201666.
7. Wang L, Li LX, Chen DQ, Yang L, Li SK, Cheng C. Low-grade Myofibroblastic sarcoma: clinical and imaging findings. *BMC Med Imaging.* 2019;19:36.
8. Hou W, Su M, Li Q, Tian R. Low-Grade Myofibroblastic Sarcoma Demonstrated on 99mTc-MDP Bone Scan and 18F-FDG PET/CT. *Clin Nucl. Med.* 2020;45:549-551.
9. Mendoza H, Nosov A, Pandit-Taskar N. Molecular imaging of sarcomas with FDG PET. *Skeletal Radiol.* 2023;52:461-475.
10. Roberts CC, Kransdorf MJ, Beaman FD, Adler RS, Amini B, Appel M, Bernard SA, Fries IB, Germano IM, Greenspan BS, Holly LT, Kubicky CD, Lo SS, Mosher TJ, Sloan AE, Tuite MJ, Walker EA, Ward RJ, Wessell DE, Weissman BN. ACR Appropriateness Criteria Follow-Up of Malignant or Aggressive Musculoskeletal Tumors. *J Am Coll Radiol.* 2016;13:389-400.